What do systematic reviews say?

Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments

Resource use and costs · people with AMD

Progression to neovascular AMD · people with AMD

Progression to geographic atrophy · people with AMD

Quality of life · people with AMD

Resource use and costs · people with AMD

Quality of life · people with AMD

Resource use and costs · people with AMD

Resource use and costs · people with AMD

Cost‐effectiveness of treatment · Participants with acute bacterial conjunctivitis

Quality of life measures at 1 month · people with acute non‐arteritic CRAO

Presence and quality of binocularity at 6 months · children with infantile esotropia

Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

Adverse effects: systemic hypotension · people with traumatic hyphema

Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema

Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema

Nausea · people with traumatic hyphema